No case consolidation (A) | Case consolidation for SoC + bezlotoxumab (B) | Case consolidation for both treatment arms (C) | |||||||
---|---|---|---|---|---|---|---|---|---|
DRG | Weighted cost savings | Budget Impact | Weighted cost savings | Budget Impact | Weighted cost savings | Budget Impact | |||
SoC | SoC + bezlo | SoC | SoC + bezlo | SoC | SoC + bezlo | ||||
B44C | 744.47 | 1,174.21 | -429.73 | 744.47 | 1,132.45 | -387.97 | 582.64 | 1,132.45 | -549.81 |
G67A | 324.13 | 935.95 | -611.83 | 324.13 | 917.38 | -593.26 | 252.17 | 917.38 | -665.21 |
G48A | 697.72 | 1,339.91 | -642.19 | 697.72 | 1,299.49 | -601.77 | 541.07 | 1,299.49 | -758.41 |
G52Z | 860.39 | 1,289.17 | -428.78 | 860.39 | 1,241.03 | -380.64 | 673.82 | 1,241.03 | -567.21 |
G77A | 908.73 | 1,423.06 | -514.33 | 908.73 | 1,370.81 | -462.08 | 706.21 | 1,370.81 | -664.59 |
G77B | 518.28 | 1,014.29 | -496.02 | 518.28 | 984.81 | -466.54 | 404.04 | 984.81 | -580.78 |
E42Z | 853.25 | 1,282.24 | -428.99 | 853.25 | 1,234.54 | -381.30 | 668.41 | 1,234.54 | -566.13 |
E79A | 555.65 | 1,111.34 | -555.69 | 555.65 | 1,079.79 | -524.14 | 433.37 | 1,079.79 | -646.42 |
T60€ | 431.28 | 984.46 | -553.18 | 431.28 | 959.83 | -528.55 | 335.83 | 959.83 | -624.00 |
F48Z | 828.86 | 1,253.70 | -424.85 | 828.86 | 1,207.61 | -378.75 | 650.20 | 1,207.61 | -557.40 |
Average | 672.27 | 1,180.83 | -508.56 | 672.27 | 1,142.77 | -470.50 | 524.78 | 1,142.77 | -618.00 |